Trial Profile
Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms PASART-2
- 01 Dec 2021 According to results published in the Acta Oncologica, after an interim analysis, a protocol was amended to reduce dose of radiotherapy to 36 Gy in 18 fractions of once daily 2 Gy for 5 days a week to reduce the risk of acute post operative wound complications
- 01 Dec 2021 Primary endpoint of pathological near complete remission of the resected specimen which has been treated with radiotherapy has not been met, according to results published in the Acta Oncologica.
- 01 Dec 2021 Results published in the Acta Oncologica